Innovent Announces Preliminary Results of a Phase I Clinical Study of IBI322 (PD-L1/CD47 Bispecific Antibody) at the 2022 AACR Annual Meeting in Subjects with Advanced Malignancies who Failed Standard Therapy

This phase I clinical study aims to evaluate the safety, tolerability and preliminary efficacy of IBI322 monotherapy in subjects with advanced malignancies who have failed standard therapy, and is divided into dose escalation phase and dose expansion phase

• A total of 20 subjects with different types of advanced malignancies received an effective dose of IBI322 (≥10 mg/kg) and completed at least one tumor assessment, of which 4 subjects achieved partial responses with an objective response rate (ORR) of 20%
  
  

  In addition, given that IBI322 has shown preliminary efficacy signals and good safety and tolerability in patients with advanced malignant tumors who have failed standard therapy, the Phase Ib clinical study of IBI322 is continuing to advance to further explore the efficacy of IBI322 in multiple indications.

  
  

  The principal investigator of this study, Professor Wang Jie of Cancer Hospital of the Chinese Academy of Sciences, said: "Immune checkpoint inhibitors have shown promising efficacy in the treatment of multiple tumor types, but there is room

  
  

  Dr.

  
  

  About IBI322

  IBI322 is a recombinant bispecific antibody specifically developed by Innovent Biopharmaceuticals against CD47/PD-L1 targets

  
  

  About Innovent

  "Begins with faith, achieves in action", and developing high-quality biological drugs affordable to the common people is the ideal and goal of Innovent

  
  

  Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model

  
  

  Innovent Bio has established a high-end biopharmaceutical development and industrialization talent team with international advanced level, including many returnee experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi in South Korea.

  
  

  statement:

  1.

  
  

  2.

  
  

  Innovent Forward-Looking Statements

  Information published in this press release may contain certain forward-looking statements

  
  

  These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, projections and understanding of future events at the time the statements are made

  
  

  The Company, its directors and employee agents disclaim (a) any obligation to correct or update the forward-looking statements contained in this website; and (b) any responsibility